Explore the categories so you can find more about your search.

Categorie > Clinical Trials / Drug Trials

Ivermectin Kills Head Lice Resistant To Standard Treatments

Categorie : Clinical Trials / Drug Trials
Head lice affect an estimated 12 million people in the United States each year, and are rapidly becoming resistant to over-the-counter and prescription medications. Researchers at the University of Massachusetts Amherst have found that ivermectin, a compound used to treat intestinal worms and plant ...

read more Head lice affect an estimated 12 million people in the United States each year, and are rapidly becoming resistant to over-the-counter and prescription medications. Researchers at the University of Massachusetts Amherst have found that ivermectin, a compound used to treat intestinal worms and plant  read more Wed Mar 2008 Wed Mar 2008

Study Finds IONSYS?, A New Needle-Free System For Management Of Acute Postoperative Pain, Requires Less Staff Compared To IV PCA Treatment

Categorie : Clinical Trials / Drug Trials
New data released at the World Congress of Anaesthesiologists (WCA) show that IONSYS? (fentanyl iontophoretic transdermal system - ITS) may save hospital staff time compared to Intravenous Patient Controlled Analgesia (IV PCA). Fentanyl ITS, a new innovative, needle-free system indicated for the man ...

read more New data released at the World Congress of Anaesthesiologists (WCA) show that IONSYS? (fentanyl iontophoretic transdermal system - ITS) may save hospital staff time compared to Intravenous Patient Controlled Analgesia (IV PCA). Fentanyl ITS, a new innovative, needle-free system indicated for the man read more Wed Mar 2008 Wed Mar 2008

SUFU 2008 Winter Meeting State Of The Art Bulbar Urethroplasty: New Perspectives On Procedure Selection

Categorie : Clinical Trials / Drug Trials
UroToday.com - In a recent meta-analysis, urethroplasty was reported to be successful in 93.3% of 443 patients with stricture length varying from 1-4cm. Although less invasive procedures are available, urethroplasty is considered the gold standard treatment for male urethral stricture. Dr. Morey del ...

read more UroToday.com - In a recent meta-analysis, urethroplasty was reported to be successful in 93.3% of 443 patients with stricture length varying from 1-4cm. Although less invasive procedures are available, urethroplasty is considered the gold standard treatment for male urethral stricture. Dr. Morey del read more Wed Mar 2008 Wed Mar 2008

Outcome Of Isolated Antenatal Hydronephrosis: A Prospective Cohort Study

Categorie : Clinical Trials / Drug Trials
UroToday.com - A study by Coelho, et al in the October 2007 issue of Pediatric Nephrology evaluated the outcome of infants with a diagnosis of antenatal hydronephrosis between May 1999 and June 2006 who were prospectively followed after a diagnosis of isolated fetal renal pelvic dilatation. The gro ...

read more UroToday.com - A study by Coelho, et al in the October 2007 issue of Pediatric Nephrology evaluated the outcome of infants with a diagnosis of antenatal hydronephrosis between May 1999 and June 2006 who were prospectively followed after a diagnosis of isolated fetal renal pelvic dilatation.  The gro read more Wed Mar 2008 Wed Mar 2008

Followup Of Patients With Interstitial Cystitis Responsive To Treatment With Intravesical Bacillus Calmette Guerin Or Placebo

Categorie : Clinical Trials / Drug Trials
UroToday.com - The Interstitial Cystitis Clinical Trials Group (ICCTG) recently reported the results of a randomized, double-blind, placebo controlled clinical trial of intravesical bacillus Calmette-Guerin (BCG). After 34 weeks of follow-up, there was no statistically significant difference betwee ...

read more UroToday.com - The Interstitial Cystitis Clinical Trials Group (ICCTG) recently reported the results of a randomized, double-blind, placebo controlled clinical trial of intravesical bacillus Calmette-Guerin (BCG).  After 34 weeks of follow-up, there was no statistically significant difference betwee read more Wed Mar 2008 Wed Mar 2008

Comparison Of Outcomes Of Vasectomy Reversal

Categorie : Clinical Trials / Drug Trials
UroToday.com - This retrospective study compared postoperative semen analysis parameters and patency rates of vasovasostomy performed in the convoluted versus straight portion of the vas deferens. This study was undertaken to assess whether or not the perceived increased technical difficulty that m ...

read more UroToday.com - This retrospective study compared postoperative semen analysis parameters and patency rates of vasovasostomy performed in the convoluted versus straight portion of the vas deferens.  This study was undertaken to assess whether or not the perceived increased technical difficulty that m read more Wed Mar 2008 Wed Mar 2008

Breakthroughs In Cancer Research At American Association For Cancer Research 2008 Annual Meeting

Categorie : Clinical Trials / Drug Trials
What:The AACR Annual Meeting features the latest cutting-edge findings in laboratory, translational and clinical cancer research. This year's meeting focuses on new and promising therapeutic approaches, as well as strides being made in diagnosing and preventing cancer.To help you take the best advan ...

read more What:The AACR Annual Meeting features the latest cutting-edge findings in laboratory, translational and clinical cancer research. This year's meeting focuses on new and promising therapeutic approaches, as well as strides being made in diagnosing and preventing cancer.To help you take the best advan read more Wed Mar 2008 Wed Mar 2008

Phase I/II Studies Of IMC-A12 In Pediatric Cancer Patients Commence Enrollment

Categorie : Clinical Trials / Drug Trials
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12, its anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibod ...

read more ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12, its anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibod read more Wed Mar 2008 Wed Mar 2008

Participants Sought For Study Of Prolotherapy For Tennis Elbow At UPMC Shadyside

Categorie : Clinical Trials / Drug Trials
The Center for Integrative Medicine (CIM) at the University of Pittsburgh Medical Center (UPMC) is seeking participants for a study to evaluate the benefits of prolotherapy for tennis elbow. Prolotherapy is a non-surgical treatment used to stimulate repair of damaged ligaments and tendons. It uses a ...

read more The Center for Integrative Medicine (CIM) at the University of Pittsburgh Medical Center (UPMC) is seeking participants for a study to evaluate the benefits of prolotherapy for tennis elbow. Prolotherapy is a non-surgical treatment used to stimulate repair of damaged ligaments and tendons. It uses a read more Wed Mar 2008 Wed Mar 2008

Cerimon To Conduct A Proof Of Concept Study For Basiliximab For Noninfectious Uveitis, A Potentially Sight-Threatening Inflammation Of The Eye

Categorie : Clinical Trials / Drug Trials
Cerimon Pharmaceuticals announced it has entered into an agreement with Novartis Pharma AG to conduct a proof of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. Uveitis can cause severe visual impai ...

read more Cerimon Pharmaceuticals announced it has entered into an agreement with  Novartis Pharma AG to conduct a proof of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. Uveitis can cause severe visual impai read more Wed Mar 2008 Wed Mar 2008

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection For More Than Six Years

Categorie : Clinical Trials / Drug Trials
New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to dat ...

read more New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to dat read more Wed Mar 2008 Wed Mar 2008

NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial For The Prevention Of Catheter Associated Urinary Tract Infections

Categorie : Clinical Trials / Drug Trials
NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com) announced that it had completed dosing of the first cohort of volunteers in a multi-cohort Phase I safety study of a bladder and catheter lavage solution of NVC-422, NovaBay's lead Aganocide compound. This clinical program ...

read more NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com) announced that it had completed dosing of the first cohort of volunteers in a multi-cohort Phase I safety study of a bladder and catheter lavage solution of NVC-422, NovaBay's lead Aganocide compound. This clinical program read more Wed Mar 2008 Wed Mar 2008

Alcon Presents Clinical Trial Data On Anecortave Acetate For Glaucoma

Categorie : Clinical Trials / Drug Trials
Alcon, Inc. (NYSE: ACL) released the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. These i ...

read more Alcon, Inc. (NYSE: ACL) released the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. These i read more Wed Mar 2008 Wed Mar 2008

GSK Statement On MHRA Investigation

Categorie : Clinical Trials / Drug Trials
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine)."The safe use of our medicines is paramount to everyone w ...

read more GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine). read more Wed Mar 2008 Wed Mar 2008

Alseres Pharmaceuticals Presents Inosine And Dopamine Transporter (DAT) Blocker Preclinical Data At The ASENT Conference

Categorie : Clinical Trials / Drug Trials
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that data from preclinical studies of the Company's nerve repair candidate, Inosine, and DAT Blocker product candidates from its neurodegeneration program were presented at the ASENT conference, March 6-8, 2008 in Arlington, VA. ...

read more Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that data from preclinical studies of the Company's nerve repair candidate, Inosine, and DAT Blocker product candidates from its neurodegeneration program were presented at the ASENT conference, March 6-8, 2008 in Arlington, VA. read more Wed Mar 2008 Wed Mar 2008

Nventa Enrolls And Initiates Dosing Of Final Cohort In HspE7 Phase 1 Cervical Dysplasia Trial

Categorie : Clinical Trials / Drug Trials
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its lead candidate, new HspE7 (HspE7 + Poly-ICLC, a toll-like ...

read more Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its  lead candidate, new HspE7 (HspE7 + Poly-ICLC, a toll-like  read more Wed Mar 2008 Wed Mar 2008

GARDASIL Will Spare Thousands A Diagnosis Of Cell Abnormality That May Lead To More Tests And Possibly Surgery

Categorie : Clinical Trials / Drug Trials
A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).The findings show the vaccine, named GARDASIL, appears to prevent the development of cell changes ...

read more A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).The findings show the vaccine, named GARDASIL, appears to prevent the development of cell changes read more Wed Mar 2008 Wed Mar 2008

Would Investigator Attendance At Review Board Reviews Be A Hindrance Or Help?

Categorie : Clinical Trials / Drug Trials
Inviting researchers to attend institutional review board sessions designed to approve these same investigators' requests to conduct research involving human subjects doesn't seem to affect the efficiency of the process one way or the other, a new study led by Johns Hopkins bioethicists suggests. ...

read more Inviting researchers to attend institutional review board sessions designed to approve these same investigators' requests to conduct research involving human subjects doesn't seem to affect the efficiency of the process one way or the other, a new study led by Johns Hopkins bioethicists suggests. read more Wed Mar 2008 Wed Mar 2008

Oramed Pharmaceuticals Successfully Completes Phase 1B Clinical Trials Of Oral Insulin Capsule

Categorie : Clinical Trials / Drug Trials
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB http://www.oramed.com), a developer of oral delivery systems, has successfully completed Phase 1B clinical trials of its oral insulin capsule. The Phase 1B trial, which utilized healthy volunteers, was focused on finding the optimal dosage for the ...

read more Oramed Pharmaceuticals, Inc. (OTCBB:  ORMP.OB http://www.oramed.com), a developer of oral delivery systems, has   successfully completed Phase 1B clinical trials of its oral insulin   capsule. The Phase 1B trial, which utilized healthy volunteers, was   focused on finding the optimal dosage for the  read more Wed Mar 2008 Wed Mar 2008

The Effect Of Shock Wave Rate On The Outcome Of Shock Wave Lithotripsy: A Meta-Analysis

Categorie : Clinical Trials / Drug Trials
UroToday.com- In this manuscript, the authors reviewed 4 randomized trials of shock wave lithotripsy comparing slow shock wave delivery (i.e. 60 shock waves/ min) to rapid shock wave delivery (120 shocks/minute), comprising 589 patients treated on 4 different lithotriptors (2 with electrohydraulic a ...

read more UroToday.com- In this manuscript, the authors reviewed 4 randomized trials of shock wave lithotripsy comparing slow shock wave delivery (i.e. 60 shock waves/ min) to rapid shock wave delivery (120 shocks/minute), comprising 589 patients treated on 4 different lithotriptors (2 with electrohydraulic a read more Fri Feb 2008 Fri Feb 2008

1 | 2 | 3 | 4 next >>>